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Genotyping and Polygenic Risk Score calculation 
For most of the participants, genotyping was performed with the Illumina OncoArray1, comprising 
533,631 SNPs. The remaining participants were genotyped with the Illumina iCOGS array, containing 
211,155 SNPs2. Details about the quality control procedures and correlation between the arrays have 
been described previously3-8. European ancestry was determined using genetic data and 
multidimensional scaling. As previously published: “We excluded individuals of non-European ancestry 
using multi-dimensional scaling. For this purpose we selected 30,733 uncorrelated autosomal SNPs 
(pair-wise r2< 0.10) to compute the genomic kinship between all pairs of BRCA1 and BRCA2 carriers, 
along with 267 HapMap samples (CHB, JPT, YRI and CEU). These were converted to distances and 
subjected to multidimensional scaling. Using the first two components, we calculated the proportion of 
European ancestry for each individual and excluded samples with >27% non-European ancestry to 
ensure that samples of Ashkenazi Jewish ancestry were included in the final sample”6. Imputation of 
variants not on genotyping arrays was performed with IMPUTE29, after prephasing with SHAPEIT10, 
using 1000 Genomes phase 3 as a reference panel. Imputation quality scores for the variants used in 
this study are shown in Table S2. 
We used the 313-variant-based PRS for breast cancer developed in an independent study using data 
from the general population as described previously11; correlation between PRS based on the two 
genotyping arrays was high8. The PRS for overall breast cancer (PRS313) and two ER-specific PRS, 
the ER-positive PRS313 and ER-negative PRS313 were calculated. For all three PRS, the same 313 
variants were used for calculation with the following formula: 




In which 𝑛𝑖𝑗 is the number of risk alleles (0, 1 or 2) for variant 𝑖 carried by individual 𝑗 and 𝑤𝑖 is the 
weight associated with variant 𝑖. All weights were derived from the analysis of data from the Breast 
Cancer Association Consortium (BCAC)11; for the ER-positive and ER-negative PRS313, ER-specific 
weights were used for the subset of 116 variants with a significant difference in the effect size by 
subtype. The variants and their corresponding weights used in the PRS are listed in Table S2 as 
published previously11. The three PRS were standardized to the mean from all CIMBA participants, 
3 
 
including both unaffected and affected women, and to the SD in BCAC population controls which were 
included in the validation dataset11. The SDs used were 0.61, 0.65 and 0.59 for the PRS313, ER-
positive PRS313 and ER-negative PRS313 respectively. Using these SDs, the HR estimates for the 
associations of the standardized PRS313 in our study are directly comparable with the OR estimates 
reported in the BCAC population-based study11 and the HR estimates reported for primary breast 









Figure S1: Flow chart of the inclusion of CIMBA participants 
Flow chart of the inclusion and exclusion of CIMBA participants for this study.  





Figure S2: Time at risk in the association analyses 
The time at risk was assumed to start one year after the first breast cancer. Participants were 
censored at (i) age at baseline, (ii) bilateral risk reducing mastectomy or (iii) death, whichever was 
earlier. Baseline age was defined as the age at local ascertainment (97%), or when this was not 
known, age at genetic testing (2%) or age at last follow-up (1%). Incidence of a metachronous 
contralateral breast cancer, invasive or in situ, before baseline was considered as an event in the main 
analyses.  
Abbreviations: BC, Breast Cancer; BRRM, Bilateral Risk Reducing Mastectomy; CBC, Contralateral 




Figure S3: Cumulative contralateral breast cancer incidence for BRCA1 and BRCA2 
heterozygotes since the first breast cancer diagnosis 
Plot of the cumulative contralateral breast cancer incidence for BRCA1 (red) and BRCA2 (blue) 
pathogenic variant heterozygotes. Confidence intervals are shown with the transparent red and blue 
color. The time of follow-up started at the age of first primary invasive breast cancer diagnosis. 




   
Figure S4: Distribution of the overall breast cancer, ER-positive and ER-negative PRS313 for 
BRCA1 and BRCA2 heterozygotes without breast cancer, with a first primary breast cancer and 
with contralateral breast cancer 
Density plots of the standardized PRS distributions for BRCA1 and BRCA2 heterozygotes. The 
distributions are shown for CIMBA participants who did not develop breast cancer (grey two-dashed 
line), who developed an invasive first primary breast cancer only (blue dashed line, selection shown in 
Figure S1) and who developed a metachronous contralateral breast cancer (red solid line). The 
number of included women for these groups were 8,837, 5,189, and 1,402 for BRCA1 heterozygotes 
and 5,665, 3,561, and 647 for BRCA2 heterozygotes.  






Table S1: Estrogen receptor status of the first primary breast tumor and the contralateral 
breast tumor 
 
ER-status BC1 ER-status CBC 
  
ER-positive ER-negative Unknown 
BRCA1 heterozygotes ER-positive 25 42 25 
ER-negative 29 256 117 
Unknown 47 148 713 
BRCA2 heterozygotes ER-positive 100 19 63 
ER-negative 16 18 27 
Unknown 81 13 310 




Table S2: 313 variants included in the polygenic risk score 




Table S3: Country of origin of included CIMBA participants 




Groupa Country    
Africa South Africa 29 70 
America Brazil 0 1 
Canada 209 103 
United States of America 1266 735 
Asia Israel 60 52 
Qatar 0 1 
Australia Australia 355 269 
Eastern Europe Albania 1 0 
Czech Republic 41 0 
Hungary 120 36 
Latvia 9 0 
Lithuania 62 6 
Poland 217 0 
Russia 12 0 
Northwestern Europe Austria 179 77 
Belgium 128 43 
Denmark 224 171 
Ireland 1 1 
Finland 46 44 
France 677 565 
Germany 762 394 
Iceland 0 102 
Netherlands 440 196 
Sweden 177 24 
United Kingdom 702 614 
Southern Europe Greece 99 13 
Italy 472 285 
Portugal 23 58 
Spain 280 348 





Table S4: Results of the association analyses between the PRS and contralateral breast cancer risk 
  
BRCA1 heterozygotes BRCA2 heterozygotes 








HR 95% CI P 
All CBC Overall BC 5,189 1,402 1.05 1.00 -1.11 0.059 3,561 647 1.15 1.07-1.24 2.33x10-4 
ER-positive  1.03 0.98-1.09 0.208 1.15 1.07-1.25 1.94x10-4 
ER-negative 1.12 1.06-1.18 5.98x10-5 1.11 1.03-1.20 0.005 
ER-positive 
CBC 
Overall BC 6,312a 279a 1.32 1.12-1.56 0.002 3,701
a 507a 1.21 1.10-1.32 4.19x10
-5 
ER-positive 1.30 1.11-1.52 0.002 1.22 1.11-1.33 2.15x10
-5 
ER-negative 1.31 1.11-1.55 0.003 1.12 1.02-1.22 0.014 
ER-negative 
CBC 
Overall BC 5,468a 1123a 0.99 0.93-1.06 0.859 4,068
a 140a 0.98 0.81-1.18 0.809 
ER-positive 0.98 0.92-1.04 0.491 0.95 0.79-1.15 0.628 
ER-negative 1.07 1.01-1.15 0.036 1.10 0.91-1.32 0.346 
a Average number over 10 imputed datasets 
Abbreviations: BC, Breast Cancer; CBC, Contralateral Breast Cancer; CI, Confidence Interval; ER, Estrogen Receptor; HR, Hazard Ratio; PRS, Polygenic 




Table S5: Results of the change in effect size of the association between the PRS and contralateral breast cancer risk, using multivariable Cox 
Regression models 
 
  BRCA1 heterozygotes; ER-negative PRS313 BRCA2 heterozygotes; ER-positive PRS313 
 




HRa 95% CI p βb % 
change 
HRb 95% CI P 
Base modelc 
 
0.111 ref 1.12 1.06-1.18 5.98x10-5 0.143 ref 1.15 1.07-1.25 1.94x10-4 
  Family history 0.112 1.10 1.12 1.06-1.18 4.43x10-5 0.143 0.26 1.15 1.07-1.25 2.53x10-4 
Age of BC1 0.112 1.03 1.12 1.06-1.18 4.32x10-5 0.151 5.01 1.16 1.08-1.26 1.29x10-4 
Tumor 
characteristics BC1 
ER-status 0.111 0.04 1.12 1.06-1.18 4.28x10-5 0.141 1.68 1.15 1.07-1.24 3.73x10-4 
Node status 0.112 0.69 1.12 1.06-1.18 4.65x10-5 0.145 1.27 1.16 1.07-1.25 2.21x10-4 
Tumor size 0.111 0.01 1.12 1.06-1.18 5.36x10-5 0.147 2.24 1.16 1.07-1.25 1.95x10-4 
Therapy BC1 Chemotherapy 0.110 0.70 1.12 1.06-1.18 5.97x10-5 0.143 0.04 1.15 1.07-1.25 2.53x10-4 
Hormone 0.111 0.10 1.12 1.06-1.18 5.15x10-5 0.144 0.14 1.15 1.07-1.25 2.48x10-4 
Trastuzumab  0.111 0.02 1.12 1.06-1.18 5.22x10-5 0.143 0.23 1.15 1.07-1.25 2.57x10-4 
Radiotherapy 0.111 0.09 1.12 1.06-1.18 5.29x10-5 0.143 0.18 1.15 1.07-1.25 2.56x10-4 
Full model All above 
variables 
combined 
0.114 2.24 1.12 1.07-1.18 4.50x10-5 0.150 4.37 1.16 1.07-1.26 2.06x10-4 
a Effect size of the ER-negative PRS313 
b Effect size of the ER-positive PRS313 
c Cox regression model for the association between the PRS and contralateral breast cancer, stratified by country, clustered on family membership, and 
adjusted for birth cohort (quartiles of the observed distribution). 
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